DE69529412D1 - Hydromorphone-therapie - Google Patents

Hydromorphone-therapie

Info

Publication number
DE69529412D1
DE69529412D1 DE69529412T DE69529412T DE69529412D1 DE 69529412 D1 DE69529412 D1 DE 69529412D1 DE 69529412 T DE69529412 T DE 69529412T DE 69529412 T DE69529412 T DE 69529412T DE 69529412 D1 DE69529412 D1 DE 69529412D1
Authority
DE
Germany
Prior art keywords
hydromorphone
therapie
oral
composition
hydroxypropylalkylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69529412T
Other languages
English (en)
Other versions
DE69529412T2 (de
Inventor
Sonya Merril
Atul D Ayer
Navjot Chadha
Anthony L Kuczynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE69529412D1 publication Critical patent/DE69529412D1/de
Application granted granted Critical
Publication of DE69529412T2 publication Critical patent/DE69529412T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
DE69529412T 1994-07-07 1995-06-23 Hydromorphone-therapie Expired - Lifetime DE69529412T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/271,593 US5529787A (en) 1994-07-07 1994-07-07 Hydromorphone therapy
PCT/US1995/007950 WO1996001629A1 (en) 1994-07-07 1995-06-23 Hydromorphone therapy

Publications (2)

Publication Number Publication Date
DE69529412D1 true DE69529412D1 (en) 2003-02-20
DE69529412T2 DE69529412T2 (de) 2003-07-31

Family

ID=23036244

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69528852T Expired - Lifetime DE69528852T2 (de) 1994-07-07 1995-06-23 Hydromorphontherapie
DE69529412T Expired - Lifetime DE69529412T2 (de) 1994-07-07 1995-06-23 Hydromorphone-therapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69528852T Expired - Lifetime DE69528852T2 (de) 1994-07-07 1995-06-23 Hydromorphontherapie

Country Status (12)

Country Link
US (2) US5529787A (de)
EP (2) EP0769949B1 (de)
AT (2) ATE230992T1 (de)
AU (1) AU693910B2 (de)
CA (1) CA2188451A1 (de)
DE (2) DE69528852T2 (de)
DK (2) DK1025845T3 (de)
ES (2) ES2186724T3 (de)
NZ (1) NZ289289A (de)
PT (1) PT1025845E (de)
WO (1) WO1996001629A1 (de)
ZA (1) ZA955674B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
WO1997033566A2 (en) * 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
EP0904118B1 (de) * 1996-05-24 2004-07-28 ALZA Corporation System zur beifügung eines nahrungsmittelzusatzes
US6190351B1 (en) * 1997-02-28 2001-02-20 Alza Corporation Nutritional support system
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
KR100748913B1 (ko) * 1999-11-22 2007-08-13 알자 코포레이션 제 1 및 제 2 를 함유하는 삼투성 투약 형태
BR0016707A (pt) 1999-12-23 2002-09-03 Pfizer Prod Inc Forma de dosagem de droga em camadas acionada por hidrogel
DZ3228A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Médicament dérivé d'un hydrogel sous forme de pastille
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
WO2002013886A2 (en) * 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
MXPA06003450A (es) 2003-09-26 2006-08-31 Johnson & Johnson Recubrimiento de farmaco que proporciona alta carga del farmaco y metodos para proporcionar el mismo.
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
WO2005030166A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Oros push-stick for controlled delivery of active agents
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US8044112B2 (en) * 2006-03-30 2011-10-25 Novartis Ag Method for applying a coating onto a silicone hydrogel lens
PL2526932T3 (pl) 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Kompozycja farmaceutyczna
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
CA2667781C (en) * 2006-10-30 2015-12-01 Novartis Ag Method for applying a coating onto a silicone hydrogel lens
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20090076135A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched hydromorphone
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (de) 2009-06-24 2012-05-02 Egalet Ltd. Retard-formulierungen
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2643291T3 (es) 2010-12-22 2017-11-22 Purdue Pharma L.P. Formas de dosificación de liberación controlada con cierre inviolable recubiertas
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5021053A (en) * 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy

Also Published As

Publication number Publication date
EP0769949B1 (de) 2003-01-15
WO1996001629A1 (en) 1996-01-25
CA2188451A1 (en) 1996-01-25
EP1025845A3 (de) 2000-12-13
DE69528852T2 (de) 2003-09-18
US5702725A (en) 1997-12-30
EP1025845B1 (de) 2002-11-13
DK0769949T3 (da) 2003-02-24
PT1025845E (pt) 2003-03-31
ES2186302T3 (es) 2003-05-01
ATE227575T1 (de) 2002-11-15
DK1025845T3 (da) 2002-12-30
EP0769949A1 (de) 1997-05-02
NZ289289A (en) 1997-10-24
DE69528852D1 (de) 2002-12-19
EP1025845A2 (de) 2000-08-09
AU2908395A (en) 1996-02-09
AU693910B2 (en) 1998-07-09
ZA955674B (en) 1996-02-20
ES2186724T3 (es) 2003-05-16
DE69529412T2 (de) 2003-07-31
ATE230992T1 (de) 2003-02-15
US5529787A (en) 1996-06-25

Similar Documents

Publication Publication Date Title
DE69529412D1 (en) Hydromorphone-therapie
DE69630615D1 (de) Verwendung einer zusammensetzung enthaltend polyether block copolymere
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
NZ328898A (en) Sustained release formulation containing collagen and glycosaminoglycan additives
NZ333385A (en) Solid oral dosage forms containing 35% of valsartan
IL144684A0 (en) Pharmaceutical composition for oral administration
MY129356A (en) Electrospun pharmaceutical compositions
NZ219948A (en) Controlled release drug delivery system for periodontal pocket
MX9600857A (es) Forma de dosificacion i en tabletas, con unidades multiples.
TNSN97010A1 (fr) Cyclopentanopyridyl-oxazolidinones contenant des heteroatomes.
IL159766A0 (en) A sustained release oral dosage form of a hydromorphone
GR3024468T3 (en) Inhalation powder containing antistatic agent.
EP0781561A4 (de) Eine neuartige medizinische verwendung eines 5ht 3?-antagonisten
EP0635559A3 (de) Wasserstoffemissionsfreie Siloxanschmierzusammensetzung.
DK0998287T3 (da) Anvendelse af levobupivacain
SI0770384T1 (en) Solid, anhydrous, pharmaceutical compositions for vaginal use
NZ332215A (en) Transdermally administered dextromethorphan as antitussive agent
IL131407A0 (en) Tetrahydropyrido compounds medicaments containing the same and the use thereof
ZA973495B (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route.
AU631334B2 (en) 2-substituted n,n'-ditrimethoxybenzoyl piperazines, and therapeutic compositions containing them
SG181694G (en) Solid oral administration forms containing ifosfamide as active agent
GB9420747D0 (en) 1,5 benzodiazepine derivatives
HK1016070A1 (en) Composition for oral administration containing pyridazinone compounds
HU9501654D0 (en) Tablet, capsule, or granule comprising desogestrel
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition